Cardiac Action Potential Assays

Cardiac action potential duration (APD) assays are recommended for candidate selection and Investigational New Drug (IND) submissions.

APD SC-derived Human Cardiomyocytes
Manual patch clamp recordings of action potentials in isolated induced pluripotent stem cell-derived human cardiomyocytes (SC-hCMs) evaluate paced intracellular electrical response for detection of drug-induced action potential prolongation and arrhythmia.

Benefits

  • Detection of action potential prolongation (QT risk) and EADs (trigger for torsades de pointes)
  • Stable recordings at physiological temperature with minimal diffusion delays
  • Human test system

APD Purkinje Fiber
Intracellular recordings of action potentials in animal Purkinje fibers evaluate paced electrical response for detection of drug-induced action potential prolongation and arrhythmia.

Benefits

  • The APD assay, together with the hERG assay, is an effective indicator of multiple ion channel effects (MICE).
  • Assays available as GLP or non-GLP

You may also be interested in...

Therapeutic Area: Cardiovascular

Charles River is your partner through the entire cardiovascular research process, from discovery through regulatory approval.

Safety Pharmacology

Charles River provides established ICH core battery tests and supplementary safety pharmacology models to meet current regulatory requirements and provide meaningful data to accurately drive your decision-making process.

CiPA: A New Day for Cardiac Safety Assessment

Advances in our understanding of the role of cardiac ion channels in arrhythmogenesis, as well as newly available in vitro technologies, have prompted implementation of a new strategy for identifying cardiac risk during drug development.